From the Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Epidemiology. 2020 Jul;31(4):570-577. doi: 10.1097/EDE.0000000000001201.
In some time-to-event analyses, it is unclear whether loss to follow up should be treated as a censoring event or competing event. Such ambiguity is particularly common in HIV research that uses routinely collected clinical data to report the timing of key milestones along the HIV care continuum. In this setting, loss to follow up may be viewed as a censoring event, under the assumption that patients who are "lost" from a study clinic immediately enroll in care elsewhere, or a competing event, under the assumption that people "lost" are out of care all together.
We illustrate an approach to address this ambiguity when estimating the 2-year risk of antiretroviral treatment initiation among 19,506 people living with HIV who enrolled in the IeDEA Central Africa cohort between 2006 and 2017, along with published estimates from tracing studies in Africa. We also assessed the finite sample properties of the proposed approach using simulation experiments.
The estimated 2-year risk of treatment initiation was 69% if patients were censored at loss to follow up or 59% if losses to follow up were treated as competing events. Using the proposed approach, we estimated that the 2-year risk of antiretroviral therapy initiation was 62% (95% confidence interval: 61, 62). The proposed approach had little bias and appropriate confidence interval coverage under scenarios examined in the simulation experiments.
The proposed approach relaxes the assumptions inherent in treating loss to follow up as a censoring or competing event in clinical HIV cohort studies.
在某些生存时间分析中,不清楚失访是否应视为删失事件还是竞争事件。这种模糊性在使用常规收集的临床数据报告 HIV 护理连续体关键里程碑时间的 HIV 研究中尤为常见。在此背景下,失访可能被视为删失事件,假设从研究诊所“丢失”的患者立即在其他地方接受护理,或者被视为竞争事件,假设“丢失”的人完全脱离护理。
我们展示了一种方法,用于解决在估计 19506 名在 2006 年至 2017 年期间参加 IeDEA 中非队列的 HIV 感染者在 2 年内开始接受抗逆转录病毒治疗的风险时的这种模糊性,同时还评估了在非洲追踪研究中公布的估计值。我们还使用模拟实验评估了拟议方法的有限样本特性。
如果将患者因失访而被删失,则治疗开始的 2 年风险估计为 69%;如果将失访视为竞争事件,则 2 年风险估计为 59%。使用拟议的方法,我们估计抗逆转录病毒治疗开始的 2 年风险为 62%(95%置信区间:61,62)。在模拟实验中检查的场景下,拟议的方法几乎没有偏差且置信区间覆盖率适当。
该方法放宽了在临床 HIV 队列研究中处理失访为删失或竞争事件所隐含的假设。